Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | GABRP | O00591 | 6/20 | 0.43 |
| ▸ | GABRD | O14764 | 6/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.43 |
| ▸ | GABRE | P78334 | 6/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880231 | 0.78 | MAPT (0.39) | THRBHTR1ACYP2C9HTR1DHTR1B | |
| SCHEMBL13377648 | 0.78 | BLM (0.51) | GABRG2GABRB3GABRA5THRBHTR1A | |
| SCHEMBL87094 | 0.78 | F10 (0.39) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11367520 | 0.76 | THRB (0.43) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9068511 | 0.75 | TP53 (0.35) | THRBMAPTF10 | |
| SCHEMBL429806 | 0.74 | F10 (0.39) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13377663 | 0.74 | KEAP1 (0.35) | THRBHTR1ACYP2C9HTR1DHTR1B | |
| SCHEMBL4019735 | 0.73 | HPGD (0.34) | GABRA1GABRA2GABRB2HTR1ASLC6A4 | |
| SCHEMBL8145288 | 0.72 | GRM5 (0.43) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL432800 | 0.72 | HTR1A (0.41) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575150-B2 | Triazole derivatives for treatment of Alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| US-20110313001-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | FISCHER CHRISTIAN (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2379075-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010077582-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20030055255-A1 | Synthesis of substituted imidazoles | MARCANTONIO KAREN (US) | 2003-03-20 | — | — | US | disclosed |
| EP-1054889-A1 | NEW OXAZOLIDINONES WITH AZOL-CONTAINING TRICYCLES | Bayer Aktiengesellschaft (DE) | 2000-11-29 | — | — | EP | disclosed |
| EP-1029854-A1 | Oxazolidinones and their use as antibacterial agents | BAYER AG (DE) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999040094-A1 | AGENT FOR SEALING METALLIC GROUND COATS, ESPECIALLY GROUND COATS CONSISTING OF ZINC OR ZINC ALLOYS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313001-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | GRM5 556/4885GABRP 1697/4885GABRD 2330/4885 |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | GRM5 911/4885GABRP 2345/4885GABRD 2531/4885 |
| US-20030055255-A1 | Synthesis of substituted imidazoles | KARS1, TKT, AADAC | GRM5 2559/4885GABRP 747/4885GABRD 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.